• Product name

    Anti-Parvovirus B 19 IgM ELISA Kit
  • Detection method

  • Precision

    Sample n Mean SD CV%
    Pos. Serum 7 2.4%
    Sample n Mean SD CV%
    Pos. Serum 21 3.6%
  • Sample type

    Serum, Heparin Plasma, Citrate Plasma
  • Assay type

  • Sensitivity

    > 95 %
  • Assay duration

    Multiple steps standard assay
  • Species reactivity

    Reacts with: Human
  • Product overview

    Abcam’s anti-Parvovirus B 19 IgM Human in vitro ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the accurate qualitative measurement of IgM class antibodies against Parvovirus B 19 in Human serum and plasma. 

    A 96-well plate has been precoated with Parvovirus B 19 antigens to bind cognate antibodies. Controls or test samples are added to the wells and incubated. Following washing, a horseradish peroxidase (HRP) labelled anti-Human IgM conjugate is added to the wells, which binds to the immobilized Parvovirus B 19 antigens. TMB is then catalyzed by the HRP to produce a blue color product that changes to yellow after adding an acidic stop solution. The intensity of yellow coloration is directly proportional to the amount of Parvovirus B 19 IgM sample captured in plate.

  • Tested applications

    Suitable for: Indirect ELISAmore details
  • Platform



  • Storage instructions

    Store at +4°C. Please refer to protocols.
  • Components Identifier 1 x 96 tests
    20X Washing Solution White cap 1 x 50ml
    Cover Foil 1 unit
    IgM Sample Diluent 1 x 100ml
    Parvovirus B 19 (IgM) Coated Microplate (12 x 8 wells) 1 unit
    Parvovirus B 19 Anti-IgM HRP Conjugate 1 x 20ml
    Parvovirus B 19 IgM Cut-off Control 1 x 3ml
    Parvovirus B 19 IgM Negative Control 1 x 2ml
    Parvovirus B 19 IgM Positive Control 1 x 2ml
    Stop Solution red cap 1 x 15ml
    Strip holder 1 unit
    TMB Substrate Solution Yellow cap 1 x 15ml
  • Research areas

  • Relevance

    Parvoviruses are cubic single-stranded DNA viruses of about 18-32 nm lacking an envelope. Parvovirus B19 infects only humans, and since there are no crossreactivities between animal parvoviruses and B19, transmission between pets and humans is not possible. Parvovirus B19 is the causative agent of Erythema infectiosum, the so-called “fifth disease”, a mild rash illness that occurs most commonly in children. Infected persons are contagious during the early part of the illness before the rash appears so in adults the rate of epidemia amounts to about 60%. About 20% of adults and children who are infected with parvovirus B19 do not develop any symptoms. Persons infected with the virus, however, do develop lasting immunity that protects them against infection in the future. Parvovirus B19 infection may cause a serious illness in persons with sickle-cell disease or similar types of chronic anemia as well as in persons who have problems with their immune system (people with leukemia or cancer, who are born with immune deficiencies, who have received an organ transplant, or who have HIV infection). Occasionally (less than 5% of all pregnant women infected with parvovirus B19) serious complications may develop during pregnancy: risk of Morbus haemolyticus fetalis.


Our Abpromise guarantee covers the use of ab178651 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Indirect ELISA Use at an assay dependent concentration.



ab178651 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab178651.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact partnerships@abcam.com

Sign up